Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EBT (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed EBT for 3 consecutive years, with -$25.5 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, EBT fell 16.25% year-over-year to -$25.5 million, compared with a TTM value of -$123.4 million through Dec 2021, down 88.32%, and an annual FY2024 reading of -$76.6 million, up 9.39% over the prior year.
  • EBT was -$25.5 million for Q4 2021 at Black Diamond Therapeutics, up from -$34.6 million in the prior quarter.
  • Across five years, EBT topped out at -$3.8 million in Q1 2019 and bottomed at -$34.6 million in Q3 2021.
  • Average EBT over 3 years is -$18.2 million, with a median of -$15.7 million recorded in 2020.
  • The sharpest move saw EBT plummeted 216.84% in 2020, then fell 16.25% in 2021.
  • Year by year, EBT stood at -$9.9 million in 2019, then crashed by 121.42% to -$21.9 million in 2020, then decreased by 16.25% to -$25.5 million in 2021.
  • Business Quant data shows EBT for BDTX at -$25.5 million in Q4 2021, -$34.6 million in Q3 2021, and -$33.8 million in Q2 2021.